A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis

Ulcerative Colitis Clinical Trial

— ACTIVE  

Official title:

A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus Infliximab to Corticosteroids Plus Azathioprine for Acute Severe Colitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02425852
• Other study ID #: GETAID 2015-02
• Status: Completed
• Phase: Phase 4
• Start date: December 2016
• Est. completion date: January 2023

Study information

• Verified date: May 2023
• Source: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

PHASE : IV TYPE OF STUDY : With direct benefit. DESCRIPTIVE : Multicentre, randomized, open label study. INCLUSION CRITERIA : Acute severe ulcerative colitis. OBJECTIVES : To compare the efficacy and safety of early administration of the combination therapy with infliximab and azathioprine with steroids and azathioprine in patients with acute severe ulcerative colitis treated with intravenous steroids.

STUDY TREATMENTS : All patients :

Intravenous steroids (0.8 mg/kg/day of methylprednisolone or equivalent) for 5 days.

Combination therapy arm:

Infliximab 5 mg/kg plus Azathioprine 2-2.5 mg/kg/day.

Azathioprine arm:

Steroids tapering for 3 months and Azathioprine 2-2.5 mg/kg/day.

Description:

NUMBER OF PATIENTS : 73 patients in each group i.e. a total of 146patients. RECRUITMENT PERIOD : 36 months STUDY DURATION : 12 months

PRIMARY END POINT : Treatment failure is defined by:

• Absence of steroid-free remission at W52 according to the total Mayo Disease Activity Index score

• OR Absence of mucosal healing (Mayo endoscopic subscore 0-1)

• OR Adverse event leading to treatment interruption

• OR Colectomy

• OR Death

• OR Infliximab withdrawal in the combination therapy group OR Infliximab introduction in the azathioprine group SECONDARY END POINT: - Clinical response and remission at D7, W14 and W52 (according to Lichtiger score and total Mayo Disease Activity Index score)

• Endoscopic and histological response

• Mucosal healing (partial endoscopic Mayo subscore 0)

• Colectomy rate

• Adverse events rate

• Fecal calprotectin

• Health-economic outcome

Recruitment information / eligibility

• Status: Completed
• Enrollment: 65
• Est. completion date: January 2023
• Est. primary completion date: June 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18 years.

• Diagnosis of UC according to Lennard-Jones criteria (Appendix 1).

• Endoscopically demonstrated colorectal lesions localized above the anal margin and extending at least up to 15cm proximally (Endoscopic Mayo subscore = 2).

• Acute flare requiring hospitalization

• Severe acute flare of UC with a Lichtiger Index score > 10 at Day -3

• Adequate contraception for male or female subjects of childbearing potential, which will be continued throughout the study and at least 3 months after study termination.

3.2 EXCLUSION CRITERIA

• Pregnant or breast-feeding woman.

• Previous treatment with infliximab.

• Treatment with adalimumab or golimumab within 8 weeks before randomization

• Treatment with vedolizumab within 4 weeks before randomization

• Azathioprine or 6-mercaptopurine treatment initiated more than 4 weeks before screening.

• Ongoing intravenous steroids for more than 96 hours at time of the screening

• Contraindication for anti-TNF therapy

• Indication for immediate surgery.

• History of colorectal dysplasia.

• Diagnosis of Crohn's disease or indeterminate colitis

• Positive stool tests for amoebiasis and/or positive bacteriological culture for Salmonella, Shigella, Yersinia and Campylobacter and/or presence of Clostridium difficile B toxin in the stools.

• Renal failure (creatininemia > upper limit of normal laboratory value).

• Uncontrolled high blood pressure.

• HIV, HBV viral infection (except the presence of positive anti-HBs antibodies) with serology not older than 3 months.

• Uncontrolled bacterial or active viral infection.

• Past medical history of malignant condition in the last 5 years (including leukaemia, lymphoma and myelodysplasia) except for baso-cellular cutaneous cancers.

• Past medical history of myocardial infarction or heart failure.

• Intradermal reaction to Tuberculin (Tubertest® 5 units) > 5mm or positive interferon-gamma release assay (Quantiferon®)

• Active tuberculosis

• Untreated latent tuberculosis (see national recommendations. Appendix 2).

• Abnormal blood count with polynuclear neutrophils < 1,500 G/L or white cells < 3,000, or platelets < 100,000 G/L.

• Unexplained rise higher than 3 times the normal level for transaminases, alkaline phosphatases and/or higher than twice the normal level for bilirubin.

• Severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in judgement of the investigator, would make the subject inappropriate for entry in this study.

• Subjects who, in the opinion of the investigator, will be uncooperative or unable to comply with study procedures.

• Participation in another clinical trial.

Related Conditions & MeSH terms

• Colitis
• Ulcerative Colitis

Intervention

Drug:
• Azathioprine
Azathioprine alone versus Azathioprine and IFX
• Infliximab

• Prednisolone

• Hydrocortisone

Locations

Country	Name	City	State
France	Chu Besancon	Besancon
France	CHU de CLERMONT FERRAND- Hopital Estain	Clermont-Ferrand
France	APHP- Hopital BEAUJON	Clichy
France	Hopital Louis Mourrier	Colombes
France	Henri Mondor Hospital	Creteil
France	Chu Kremlin Bicetre	Le Kremlin-Bicêtre
France	CHRU Lille	Lille
France	Chu Montpellier	Montpellier
France	CHU de NICE- Hopital Archet 2	Nice
France	Hopital Saint Joseph	Paris
France	Hopital Saint Louis	Paris
France	Hopital St Antoine	Paris
France	CHU RENNES - Hopital Pontchaillou	Rennes
France	Chu Rouen	Rouen
France	Chu Saint Etienne	St Etienne
France	CHU NANCY - Hopital Brabois	Vandoeuvre Les Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of patients with treatment failure at week 52.	Failure is defined as: absence of steroid-free remission (Total Mayo Disease Activity Index (DAI) score = 2 with no individual subscore > 1); absence of mucosal healing (Endoscopic Mayo DAI subscore = 1); or severe adverse event leading to treatment interruption between day 0 and week 52; or colectomy between day 0 and week 52; or fatality between day 0 and week 52; or infliximab withdrawal for failure and /or intolerance in the combination therapy group; or any biological agent introduction in the azathioprine group	Week 52
Secondary	Percentage of patients in clinical response at day 7	Percentage of patients in clinical response at day 7 (Lichtiger Index score<10 with a decrease of at least 3 points compared with the baseline score) and at week 14 and week 52 (a decrease from baseline in the Mayo score =30% and =3 points, accompanied by either a rectal bleeding subscore of 0 or 1 or a decrease from baseline in the rectal bleeding subscore =1); - Percentage of patients in clinical remission at day 7, week 14 and week 52	7 days